

Global Markets for Infectious Disease Treatments

<https://marketpublishers.com/r/G211D0E8CA2EN.html>

Date: December 2021

Pages: 245

Price: US\$ 2,750.00 (Single User License)

ID: G211D0E8CA2EN

Abstracts

Report Scope:

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, and diagnostic kits, recently launched or in development. Market share, market deterrents, unmet needs and other factors that drive research are also discussed, while patents that highlight research priorities and predict future trends are analyzed.

Specifically, outside the scope of research are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion on the spread of vector-borne infection (such as malaria) via blood-transfusion.

BCC Research categorizes the markets based on regions defined by WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships for a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific.

Report Includes:

113 tables

An updated review of the global markets for infectious disease treatments in the healthcare and pharmaceutical industry

Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026

Evaluation and forecast the overall market size in dollar value terms, and corresponding market share analysis by disease type and geographic region

Highlights of the market potential for infectious disease treatments, opportunities and gaps estimating current and future demand; and impact of COVID-19 on the progress of this market

Emphasis on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development

Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans

Technology assessment of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated

Insight into the competitive landscape featuring key mergers and acquisitions (M&A), collaboration agreements, and company revenue share analysis across the global infectious diseases market

Review of key patent grants and new technologies with relate to innovations in infectious disease treatments

Company profiles of the leading industry participants including Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, and Roche

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Update?
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 OVERVIEW

Top Global Causes of Death
Infectious Diseases
Classification of Infectious Agents
Classification of Modes of Transmission
Management of Infectious Diseases
Bacterial Infectious Diseases
Viral Infectious Diseases
Protozoan Infectious Diseases
Factors Responsible for Emergence and Spread
Vaccines
Antibiotics
Mechanism of Action

CHAPTER 4 DISEASE OVERVIEW

Hepatitis B and Hepatitis C
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden

Diagnosis
Treatment
Herpes Simplex Virus
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
HIV/AIDS
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Influenza A and Influenza B
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Rotavirus
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Respiratory Syncytial Virus
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Malaria
Incidence and Geographical Distribution

Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Tuberculosis
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Viral Hemorrhagic Fevers-Lassa Fever
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Viral Hemorrhagic Fevers-Ebola Fever
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Response to Manage Ebola
Diagnosis
Treatment
Viral Hemorrhagic Fevers-Marburg
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment

Viral Hemorrhagic Fevers-Zika Virus
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Viral Hemorrhagic Fevers-Yellow Fever
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment
Viral Hemorrhagic Fevers-Dengue
Incidence and Geographical Distribution
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Diagnosis
Treatment

CHAPTER 5 MARKET DYNAMICS

Infectious Diseases
Drivers
Deterrents
Hepatitis B
Drivers
Deterrents
Unmet Needs
Hepatitis C
Drivers
Deterrents
Unmet Needs
Herpes
Drivers
Deterrents
Unmet Needs

HIV/AIDS

Drivers

Deterrents

Unmet Needs

Influenza A and B

Drivers

Deterrents

Rotavirus

Drivers

Deterrents

Unmet Needs

Respiratory Syncytial Virus

Drivers

Deterrents

Unmet Needs

Malaria

Drivers

Deterrents

Unmet Needs

Tuberculosis

Drivers

Deterrents

Unmet Needs

MERS-CoV

Drivers

Deterrents

Unmet Needs

Viral Hemorrhagic Fevers-Lassa

Drivers

Deterrents

Unmet Needs

Viral Hemorrhagic Fevers-Ebola

Drivers

Deterrents

Viral Hemorrhagic Fevers-Marburg

Drivers

Deterrents

Unmet Needs

Viral Hemorrhagic Fevers-Zika

Drivers
Deterrents
Viral Hemorrhagic Fevers-Yellow Fever
Drivers
Deterrents
Unmet Needs
Viral Hemorrhagic Fevers-Dengue
Drivers
Deterrents
Unmet Needs

CHAPTER 6 IMPACT OF COVID-19

History of Outbreak
Symptoms of COVID-19
Progression of COVID-19
Incubation Period
Epidemiology
Impact of COVID-19 on Infectious Disease Market

CHAPTER 7 MARKETS AND FORECAST

Global Market for Infectious Disease Treatments
Global Market for Infectious Disease Treatments by Region
Global Market for Infectious Disease Therapeutics by Disease Type
Global Market for Infectious Disease Vaccines by Disease Type
Global Market for Infectious Disease Diagnostics by Disease Type
Global Infectious Diseases
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza-A and B
Rotavirus
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS-CoV
Viral Hemorrhagic Fevers

CHAPTER 8 ANTIBIOTIC RESISTANCE

Overview
Mechanisms of Antibiotic Resistance
Reasons for Antibiotic Resistance
Antibiotic Resistance-Incidence
New Antibiotics in Development

CHAPTER 9 RESEARCH AND DEVELOPMENT

Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Rotavirus
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika

CHAPTER 10 NEXT-GENERATION PREDICTIVE TOOLS

Overview
Why Do We Need Forecast Tools?
Tools in Infectious Disease Modeling
Mobile Apps in Infectious Disease Modeling
Current Limitations in Infectious Disease Modeling

CHAPTER 11 PATENT ANALYSIS

Hepatitis B

Key Patents
Hepatitis C
Key Patents
Herpes Simplex Virus
Key Patents
HIV/AIDS
Key Patents
Influenza
Key Patents
Rotavirus
Key Patents
Respiratory Syncytial Virus
Key Patents
Malaria
Key Patents
Tuberculosis
Key Patents
MERS-CoV
Key Patents
Viral Hemorrhagic Fevers-Lassa
Key Patents
Viral Hemorrhagic Fevers-Ebola
Key Patents
Viral Hemorrhagic Fevers-Marburg
Key Patents
Viral Hemorrhagic Fevers-Zika
Key Patents
Viral Hemorrhagic Fevers-Dengue
Key Patents
Viral Hemorrhagic Fevers-Yellow Fever

CHAPTER 12 COMPETITIVE LANDSCAPE

Mergers and Acquisitions and Collaborations
Market Share of Infectious Disease Market
Market for Hepatitis B and Hepatitis C
Market Shares of HIV/AIDS Therapeutics
Market Shares of Influenza Vaccines
Market Shares of Rotavirus Vaccines

CHAPTER 13 COMPANY PROFILES

ABBOTT
ABBVIE INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB CO.
DIASORIN S.P.A.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MERCK & CO, INC.
NOVARTIS AG
ORASURE TECHNOLOGIES INC.
ROCHE
SANOFI S.A.
SEQIRUS, A CSL CO.
SIEMENS HEALTHINEERS

CHAPTER 14 APPENDIX: ABBREVIATIONS

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Infectious Disease Treatments, by Segment, Through 2026

Table 1: Leading Causes of Death, Worldwide, by Region, 2019

Table 2: Leading Causes of Death Due to Infectious Diseases, by Region, 2019

Table 3: Prevalence and Incidence of Hepatitis B, 2019

Table 4: Prevalence and Incidence of Hepatitis C, 2019

Table 5: Global Death Rate Related to Acute Hepatitis B, 1990-2019

Table 6: Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019

Table 7: Prevalence and Incidence of Genital Herpes, Worldwide, 2005-2019

Table 8: Prevalence of HIV, Adults (15-49 Years Old), by Region, 2020

Table 9: New HIV Infections (per 1,000 Uninfected Population), Among all Ages, by Region, 2020

Table 10: Total Number of New HIV Infections, 2000-2020

Table 11: Cases of HIV/AIDS Related Deaths, 2000-2020

Table 12: Years of Life Lost (YLLs), Pandemic Influenza A, H1N1, by Region, 2009

Table 13: Estimates of Number of RSV Cases per Season for 15 Participating Countries, 2000-2020

Table 14: Death Rates of RSV-Infected Patients, by WHO Region, 2019

Table 15: Global Incidence Rate of Malaria Cases, by Region, 2000-2019

Table 16: Global Confirmed Cases of Malaria in Public Sector, by Region, 2010-2019

Table 17: Deaths Due to Malaria Worldwide, by Region, 2010-2019

Table 18: Global Health Expenditures on Malaria Treatment, by Region, 2019

Table 19: WHO Guidelines for Treatment of Malaria

Table 20: Treatment Regimen, Drug-Susceptible TB

Table 21: MERS-CoV Confirmed Cases and Deaths, by Region, January 2016-October 2021

Table 22: Laboratory Tests for MERS CoV, as Recommended by WHO

Table 23: Lassa Fever, Confirmed Cases and Deaths, by Region, January 2006-April 2020

Table 24: Reported Cases and Deaths in Ebola Outbreaks, 2007-February 2021

Table 25: Reported Cases and Deaths in Marburg Virus, 1998-December 2020

Table 26: Global Health Burden due to Outbreak of Zika Virus, by Country, 2015-2016

Table 27: Potential Cases and Deaths Due to Yellow Fever, 1995-2018

Table 28: Disease Burden–Yellow Fever in Africa, 2019

Table 29: Deaths Averted due to Mass Vaccinations in Africa, 2019

- Table 30: Global Prevalence and Incidence of Dengue, 2019
- Table 31: COVID-19 Confirmed Cases and Deaths, by Region, as of November 2020
- Table 32: Global Market for Infectious Disease Treatment, by Region, Through 2026
- Table 33: Global Market for Infectious Disease Therapeutics, by Disease Type, Through 2026
- Table 34: Global Market for Infectious Disease Vaccines, by Disease Type, Through 2026
- Table 35: Global Market for Infectious Disease Diagnostics, by Disease Type, Through 2026
- Table 36: Global Market for Hepatitis B Therapeutics, by Region, Through 2026
- Table 37: Global Market for Hepatitis B Vaccines, by Region, Through 2026
- Table 38: Global Market for Hepatitis B Diagnostics, by Region, Through 2026
- Table 39: Global Market for Hepatitis C Therapeutics, by Region, Through 2026
- Table 40: Global Market for Hepatitis C Diagnostics, by Region, Through 2026
- Table 41: Global Market for HSV Therapeutics, by Region, Through 2026
- Table 42: Global Market for HSV Diagnostics, by Region, Through 2026
- Table 43: Global Market for HIV Therapeutics, by Region, Through 2026
- Table 44: Global Market for HIV Diagnostics, by Region, Through 2026
- Table 45: Global Market for Influenza Vaccines, by Region, Through 2026
- Table 46: Global Market for Influenza Diagnostics, by Region, Through 2026
- Table 47: Global Market for Rotavirus Vaccines, by Region, Through 2026
- Table 48: Global Market for Rotavirus Diagnostics, by Region, Through 2026
- Table 49: Global Market for RSV Vaccines, by Region, Through 2026
- Table 50: Global Market for RSV Diagnostics, by Region, Through 2026
- Table 51: Global Market for Malaria Therapeutics, by Region, Through 2026
- Table 52: Global Market for Malaria Vaccines, by Region, Through 2026
- Table 53: Global Market for Malaria Diagnostics (RDTs*), by Region, Through 2026
- Table 54: Global Market for Tuberculosis Therapeutics, by Region, Through 2026
- Table 55: Global Market for Tuberculosis Diagnostics, by Region, Through 2026
- Table 56: Global Market for MERS-CoV Vaccines, by Region, Through 2026
- Table 57: Global Market for Lassa Fever Vaccines, by Region, Through 2026
- Table 58: Global Market for Ebola Fever Vaccines, Through 2026
- Table 59: Global Market for Zika Vaccines, by WHO Region, Through 2026
- Table 60: Global Market for Yellow Fever Vaccines, by WHO Region, Through 2026
- Table 61: Global Market for Dengue Vaccines, by Region, Through 2026
- Table 62: Reported Range of Resistant Population Proportion (%), by Region
- Table 63: WHO Priority List, Pathogens for R&D of New Antibiotics
- Table 64: Global Antibiotics Development Pipeline
- Table 65: Hepatitis B and Hepatitis C Development Pipeline

Table 66: Herpes Simplex Virus Development Pipeline

Table 67: HIV/AIDS Development Pipeline

Table 68: Influenza A and Influenza B Development Pipeline

Table 69: Rotavirus Development Pipeline

Table 70: RSV Development Pipeline

Table 71: Malaria Development Pipeline and Recent Launches

Table 72: Tuberculosis Development Pipeline

Table 73: MERS Development Pipeline

Table 74: Dengue Development Pipeline

Table 75: Ebola Development Pipeline

Table 76: Lassa Fever Development Pipeline

Table 77: Marburg Development Pipeline

Table 78: Yellow Fever Development Pipeline

Table 79: Zika Development Pipeline

Table 80: Hepatitis B Published Patent Applications, 2018-2021

Table 81: Hepatitis C Published Patent Applications, 2018-2021

Table 82: Herpes Simplex Virus Published Patent Applications, 2018-2021

Table 83: HIV/AIDS Published Patent Applications, 2018-2021

Table 84: Influenza Published Patent Applications, 2018-2021

Table 85: Rotavirus Published Patent Applications, 2018-2021

Table 86: Respiratory Syncytial Virus Published Patent Applications, 2018-2021

Table 87: Malaria Published Patent Applications, 2018-2021

Table 88: Tuberculosis Published Patent Applications, 2018-2021

Table 89: MERS Published Patent Applications, 2018-2021

Table 90: Lassa Fever Published Patent Applications, 2018-2021

Table 91: Ebola Virus Published Patent Applications, 2018-2021

Table 92: Marburg Virus Published Patent Applications, 2018-2021

Table 93: Zika Published Patent Applications, 2018-2021

Table 94: Dengue Fever Published Patent Applications, 2018-2021

Table 95: Yellow Fever Published Patent Applications, 2018-2021

Table 96: Abbott: Product Portfolio, by Business Segment

Table 97: Abbott: Financials, 2018-2020

Table 98: AbbVie: Business Segments

Table 99: AbbVie: Financial Performance, Through 2020

Table 100: Bristol-Myers Squibb: Financial Performance, 2018-2020

Table 101: Gilead Sciences: Financial Performance, 2018-2020

Table 102: GlaxoSmithKline: Product Segments

Table 103: GlaxoSmithKline: Financial Performance, 2018-2020

Table 104: Johnson & Johnson: Business Segments

Table 105: Johnson & Johnson: Financial Performance, 2018-2020

Table 106: Merck: Business Segments

Table 107: Merck: Financial Performance, 2018-2020

Table 108: Roche: Business Segments

Table 109: Roche: Financial Performance, 2018-2020

Table 110: Sanofi: Business Segments

Table 111: Sanofi: Financial Performance, 2018-2020

Table 112: Abbreviations Used in this Report

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Infectious Disease Treatments, by Segment, 2020-2026

Figure 1: 20 Leading Causes of Death, Worldwide, 2019

Figure 2: Leading Causes of Death, Worldwide, by Region, 2019

Figure 3: Leading Causes of Death Due to Infectious Diseases, by Region, 2019

Figure 4: Global Vaccination Coverage, by Vaccine, 2020

Figure 5: Global Death Rate Related to Acute Hepatitis B, 1990-2019

Figure 6: Years of Life (YLLs) Lost Related to Acute Hepatitis B, Worldwide, 2016-2019

Figure 7: Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019

Figure 8: Years of Life (YLLs) Lost Related to Acute Hepatitis C, Global, 2016-2019

Figure 9: Disability-affected Life Years (DALYs) Caused by Genital Herpes, Worldwide, 1990-2019

Figure 10: New HIV Infections, by Region, Worldwide, 2020

Figure 11: HIV/AIDS Related Deaths, by Region, 2020

Figure 12: Estimated Number of Deaths Due to 2009 Pandemic Influenza A H1N1, by Region, August 2009-August 2010

Figure 13: Number of Deaths Due to Rotavirus, Worldwide, 2015-2019

Figure 14: Highest Number of Infant Deaths Due to Rotavirus, by Country, 2017

Figure 15: Death Caused by Malaria Worldwide, 2015-2019

Figure 16: Global Incidence of Tuberculosis, 2015-2020

Figure 17: Deaths due to Tuberculosis, Worldwide, 1990-2019

Figure 18: Disability-Adjusted Life Years Caused by Tuberculosis, Worldwide, 1990-2019

Figure 19: Incidence of Cases and Deaths from Lassa Fever in Nigeria, 2017-2020

Figure 20: Total Number of Cases due to Ebola Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), March 2014-February 2016

Figure 21: Deaths Due to Ebola Outbreaks in West Africa (Guinea, Liberia, Sierra Leone), March 2014-February 2016

Figure 22: Cases and Deaths Due to Major Marburg Outbreaks, 1998–June 2017

Figure 23: Confirmed Zika Virus Cases in the Americas, 2015-2020

Figure 24: Countries (Y) with Number of Confirmed Zika Cases (X) in the Americas, 2015-2016

Figure 25: Global Disability-Adjusted Life Years (DALYs) Due to Yellow Fever, 1995-2019

Figure 26: Deaths Caused by Yellow Fever, Worldwide, 1995-2019

- Figure 27: Total Number of Dengue Cases Reported in the Americas, 2016-2020
- Figure 28: Incidence Rate of Dengue in the Americas, 2016-2020
- Figure 29: Deaths Caused by Dengue, Worldwide, 2015-2019
- Figure 30: Dengue-Caused Years of Life Lost, Worldwide, 2015-2019
- Figure 31: Global Market for Hepatitis B Vaccines, by Region, 2019–2026
- Figure 32: Global Market for Hepatitis B Vaccines, by Region, 2019–2026
- Figure 33: Global Market for Hepatitis B Diagnostics, by Region, 2019-2026
- Figure 34: Global Market for Hepatitis C Therapeutics, by Region, 2019-2026
- Figure 35: Global Market for Hepatitis C Diagnostics, by Region, 2019–2026
- Figure 36: Global Market for HSV Therapeutics, by Region, 2019-2026
- Figure 37: Global Market for HSV Diagnostics, by Region, 2019-2026
- Figure 38: Global Market for HIV/AIDS Therapeutics, by Region, 2019-2026
- Figure 39: Global Market for HIV Diagnostics, by Region, 2019–2026
- Figure 40: Global Market for Influenza Vaccines, by Region, 2019-2026
- Figure 41: Global Market for Influenza Diagnostics, by Region, 2019-2026
- Figure 42: Global Market for Rotavirus Vaccines, by Region, 2019-2026
- Figure 43: Global Market for Rotavirus Diagnostics, by Region, 2019-2026
- Figure 44: Global Market for RSV Vaccines, by Region, 2019-2026
- Figure 45: Global Market for RSV Diagnostics, by Region, 2019-2026
- Figure 46: Global Market for Malaria Therapeutics, by Region, 2019-2026
- Figure 47: Global Market for Malaria Diagnostics (RDTs*), by Region, 2019-2026
- Figure 48: Global Market for Tuberculosis Therapeutics, by Region, 2019-2026
- Figure 49: Global Market for Tuberculosis Diagnostics, by Region, 2019-2026
- Figure 50: Global Market for MERS-CoV Vaccine, by Region, 2019-2026
- Figure 51: Global Market for Lassa Fever Vaccines, by Region, 2020-2026
- Figure 52: Global Market for Zika Vaccines, by WHO Region, 2019-2026
- Figure 53: Global Market for Yellow Fever Vaccines, by WHO Region, 2019-2026
- Figure 54: Global Market for Dengue Vaccines, by Region, 2019-2026
- Figure 55: Antibiotic Use* by Class, Select Classes, 2000 and 2010
- Figure 56: Shares of Companies in the Global Market for Hepatitis B and C, 2020
- Figure 57: Shares of Companies in the Global Market for HIV/AIDS Therapeutics, 2020
- Figure 58: Shares of Companies in the Global Market for Influenza Vaccines, 2020
- Figure 59: Shares of Companies in the Global Market for Rotavirus Vaccines, 2020
- Figure 60: Abbott: Revenue Share, by Region, 2020
- Figure 61: Abbott: Revenue Share, by Business Segment, 2020
- Figure 62: AbbVie: Net Revenue Share, by Business Segment, 2020
- Figure 63: AbbVie: Net Revenue Share, by Region, 2020
- Figure 64: Bristol Myers Squibb: Sales Share, by Product, 2020
- Figure 65: Bristol-Myers Squibb: Revenue Share, by Region, 2020

Figure 66: Gilead Sciences: Sales Share, by Product, 2020

Figure 67: Gilead Sciences: Revenue Share, by Region, 2020

Figure 68: GlaxoSmithKline: Sales Share, by Product Segment, 2020

Figure 69: GlaxoSmithKline: Revenue Share, by Region, 2020

Figure 70: Johnson & Johnson: Sales Share, by Business Segment, 2020

Figure 71: Johnson & Johnson: Revenue Share, by Region, 2020

Figure 72: Merck: Revenue Share, by Business Segment, 2020

Figure 73: Merck: Revenue Share, by Region, 2020

Figure 74: Roche: Sales Share, by Product Segment, 2020

Figure 75: Roche: Revenue Share, by Region, 2020

Figure 76: Sanofi: Sales Share, by Business Segment, 2020

Figure 77: Sanofi: Sales Share, by Region, 2020

I would like to order

Product name: Global Markets for Infectious Disease Treatments

Product link: <https://marketpublishers.com/r/G211D0E8CA2EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G211D0E8CA2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970